Breast Cancer is a global problem. In the U.S. nearly one in eight women will develop Breast Cancer in their lifetime. This translates to > 200,000 new cases of Breast Cancer and, despite existing therapies, > 40,000 deaths per year in U.S. Importantly, there is also an unmet need for targeted therapy for highly aggressive triple negative Breast Cancer. JAA-F11 can meet these needs targeting 80% of all Breast Cancer (competitor Herceptin targets only 25% with Her-2).
Our technology will treat primary and metastatic cancer. Given that cancer deaths are mostly due to metastasis and TF-Ag plays a critical role in the metastasis process, JAA-F11 along with direct killing has long term potential to block metastasis extending patient survival. JAA-F11 is expected to be safe as humans have small amounts of naturally occurring antibody to the TF-Ag. Recent in vivo efficacy studies show potential for lung cancer as well.
De-risking and validation through the non-dilutive partnership with the NCI Experimental Therapeutics (NExT) program provides For-Robin with resources to bring hJAA-F11 through the FDA IND to first in human clinical trials, by Spring 2021.
For-Robin is seeking partner(s) and investors to support 1) extended Phase I clinical trials in lung and breast cancer therapy with humanized JAA-F11 antibody (hJAA-F11) and/or 2) clinical trials of differential imaging diagnostic applications of hJAA-F11 in lung cancer.
Currently funded by 1 R43 CA236023-01A1 (4/1/19-3/31/20) JAA-F11 Anti-Thomsen-Friedenreich Antigen Targeted Imaging for Lung Cancer Differential Diagnosis and 2R42 CA176951-02A1 STTR NIH Phase II: 5/1/15 - 4/31/19. Total raised to date: $2,827,000.